

Delisting of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) products from the *Alberta Drug Benefit List (ADBL)*

Effective October 1, 2025, the Retina Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Program for Intraocular Disease (RAPID) was replaced with the Alberta Retinal Treatment Program (ARTP).

To support program implementation and ensure a single point of access for these therapies at no cost to eligible Albertans, the following products will be delisted from the *ADBL* effective **November 1, 2025**.

DIN	Product Description
02496976	Beovu 6 mg/0.05 mL Injection Syringe
02415992	Eylea 2 mg/vial Injection
02296810	Lucentis 2.3 mg/vial Injection
02527618	Vabysmo 6 mg/0.05 mL vial Injection

A **60-day transition period** will be applied and as of January 1, 2026 claims will no longer pay for these products through the *ADBL*.

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross® has confirmed that the shortage for Sandoz Morphine SR 15 mg Sustained-Release Tablet (DIN 02244790) and Teva-Morphine SR 15 mg Sustained-Release Tablet (DIN 02302764) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **November 28, 2025**. The following grouping was removed from the Critical Supply Product List **October 29, 2025**.

MORPHINE SULFATE

15 MG SUSTAINED-RELEASE TABLET

00002244790	SANDOZ MORPHINE SR	SDZ	\$0.4145
00002302764	TEVA-MORPHINE SR	TEV	\$0.4145
00002015439	MS CONTIN	PUR	\$ 0.8485

continued next page

continued from previous page

Removal of Temporary Benefits from ADBL

Due to the unavailability of Apo-Amphetamine XR 15 mg Extended-Release Capsule (DIN 02445514), Sandoz Amphetamine XR 15 mg Extended-Release Capsule (DIN 02457318) and Teva-Amphetamine XR 15 mg Extended-Release Capsule (DIN 02439255), **Adderall XR 15 mg Extended-Release Capsule (DIN 02248810)** manufactured by Takeda Canada, Inc., was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross has confirmed that the shortage for Sandoz Amphetamine XR 15 mg Extended-Release Capsule (DIN 02457318) and Teva-Amphetamine XR 15 mg Extended-Release Capsule (DIN 02439255) has been resolved.

Adderall XR 15 mg Extended-Release Capsule (DIN 02248810) will no longer be considered temporary benefits for the *ADBL* after **December 4, 2025**. The above grouping was removed from the Critical Supply Product List **November 4, 2025**.

Due to the unavailability of Anodan-HC 10 mg Rectal Suppository (DIN 02236399), manufactured by Odan Laboratories Ltd., **Anusol-HC 10 mg/10 mg Rectal Suppository (DIN 00476285)** manufactured by Church & Dwight Canada, was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross has confirmed that the shortage for Anodan-HC 10 mg Rectal Suppository (DIN 02236399) has been resolved.

Anusol-HC 10 mg/10 mg Rectal Suppository (DIN 00476285) will no longer be considered a temporary benefit for the *ADBL* after **December 4, 2025**. The above grouping was removed from the Critical Supply Product List **November 4, 2025**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)
403-294-4041 (Calgary and area)
1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area)
FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct-bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

